Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma

Roberto A. Perego, Matteo Corizzato, Paola Brambilla, Stefano Ferrero, Cristina Bianchi, Ester Fasoli, Stefano Signorini, Barbara Torsello, Lara Invernizzi, Silvia Bombelli, Valentina Angeloni, Marina Pitto, Cristina Battaglia, Vanessa Proserpio, Fulvio Magni, Giacomo Galasso, Paolo Mocarelli

Research output: Contribution to journalArticlepeer-review


We verified the feasibility of plasma bound method for detecting renal cell carcinoma (RCC) combining the study of plasma DNA concentration and microsatellite alterations (LOH). Plasma DNA concentration was evaluated with real-time PCR in 54 patients with renal neoplasm before surgery and in 20 of these patients during a 26-64 month follow-up. Microsatellite study was performed on tumour tissue DNA of 33 RCC clear cell (RCCcc) and on plasma DNA of 14 RCCcc patients during preoperative and/or follow-up period. Patients had a significantly high (26.4 ± 48.3 ng/ml versus controls 3.2 ± 1.5 ng/ml; p = 0.003) preoperative plasma DNA concentration that decreased after nephrectomy. During follow-up, plasma DNA increased in 12 patients without evidence of neoplasia; 3 patients successively relapsed. Tumour tissue DNA of 25 RCCcc patients (75.8%) displayed microsatellite LOH. Preoperative plasma DNA of 9 patients harboured LOH in 5 cases (55.6%). Augmented plasma DNA of 7 patients displayed LOH in 3 cases (42.9%) at follow-up, and in 1 case preceded the recurrence of disease. Plasma DNA concentration combined with microsatellite LOH in plasma DNA may predict disease recurrence in RCC patients.

Original languageEnglish
Pages (from-to)1039-1047
Number of pages9
JournalEuropean Journal of Cancer
Issue number7
Publication statusPublished - May 2008


  • Follow-up
  • Microsatellite LOH
  • Plasma DNA concentration
  • Renal cell carcinoma
  • Tumour markers

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma'. Together they form a unique fingerprint.

Cite this